Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

By S. Schulman, C. Kearon, A. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, David Baanstra, J. Schnee, Samuel Z. Goldhaber. New England Journal of Medicine, 2009

2,549 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/a3bdb4fd03fae806d9ab7fd10f425862ce43720a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Schulman
2. G. Agnelli
3. Jeroen J. Bax
4. Jose Luis Zamorano
5. Alejandro Rabinstein
6. B. Cravatt
7. P. Lancellotti
8. J. Stangier

In Hematology

1. B. Cravatt
2. J. Stangier
3. D. Bachovchin
4. S. Konstantinides

In Internal Medicine

1. Samuel Z. Goldhaber
2. B. Cravatt
3. G. Agnelli
4. D. Bachovchin
5. S. Konstantinides
6. H. Büller

Citations in the corpus

• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010, background): “Other indications under investigation include the treatment of venous thromboembolism (VTE) (5) and treatment of thromboembolic complications following acute coronary syndromes (6).”
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “However, only 3 9% of patients included in phase III studies with NOACs for the treatment of VTE had concomitant cancer.(260,261,312,314,351) A randomized, open-label trial compared edoxaban with LMWH in the secondary prevention of VTE in 1050 patients with cancer-associated thrombosis (mostly sympt”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “For example, in the International Cooperative Pulmonary Embolism Registry (ICOPER), age .70 years, systolic BP ,90 mm Hg, respiratory rate .20 breaths/min, cancer, chronic heart failure and chronic obstructive pulmonary disease (COPD), were all identified as prognostic factors.48 In the Registro Inf”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, methodology): “For example, in the International Cooperative Pulmonary Embolism Registry (ICOPER), age .70 years, systolic BP ,90 mm Hg, respiratory rate .20 breaths/min, cancer, chronic heart failure and chronic obstructive pulmonary disease (COPD), were all identified as prognostic factors.48 In the Registro Inf”